Anne Marie Lane

Ms. Anne Marie Lane


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Ophthalmology
Verified
Journal Article
Closed access
ALAnne Marie Lane
Anne Marie Lane
KEKathleen M. Egan
Kathleen M. Egan
DHDavid Harmon
David Harmon
AHAmy Holbrook
Amy Holbrook
JMJohn E. Munzenrider
John E. Munzenrider
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas

1 September 2011 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
ALAnne Marie Lane
Anne Marie Lane
IKIvana K Kim
Ivana K Kim
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
Research from JAMA Ophthalmology — Proton Irradiation for Peripapillary and Parapapillary Melanomas

1 August 2010 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
ALAnne Marie Lane
Anne Marie Lane
KEKathleen M. Egan
Kathleen M. Egan
IKIvana K Kim
Ivana K Kim
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
There is considerable evidence that intraocular melanomas arise from benign pigmented precursor lesions (nevi) in the uveal tract. In histopathological sections of uveal melanomas, nevoid cells can be identified at the base of many tumors,1 and there are documented cases of uveal melanomas arising from preexisting nevi.2 Also, persons with large numbers of cutaneous3-7 and iris6-8 nevi are at heightened risk of developing melanomas in the posterior uveal tract (ie, the choroid and ciliary body).

16 May 2022 in Ophthalmology Retina
Verified
Journal Article
Closed access
ALAnne Marie Lane
Anne Marie Lane
MOMonica M. Oxenreiter
Monica M. Oxenreiter
MHMustafa Hashmi
Mustafa Hashmi
MAMary E. Aronow
Mary E. Aronow
ATAlexei V. Trofimov
Alexei V. Trofimov
IKIvana K Kim
Ivana K Kim

3 July 2023 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
ALAnne Marie Lane
Anne Marie Lane
CHCaleb Hartley
Caleb Hartley
AGAshley K Go
Ashley K Go
FWFrances Wu
Frances Wu
EGEvangelos S Gragoudas
Evangelos S Gragoudas
IKIvana K Kim
Ivana K Kim
Background/aims We evaluated a large cohort of patients treated for local recurrence of choroidal or ciliary body melanomas at the Massachusetts Eye and Ear (MEE) to quantify the risk of melanoma-related mortality associated with recurrence, independent of other risk factors. Methods Patients treated with radiation therapy from 1982 to 2017 were identified through the Uveal Melanoma Registry at MEE. Competing risks regression was performed to investigate the risk of melanoma-related mortality associated with recurrence, treating recurrence as a time-varying covariate. Results Of 4196 patients treated, 4043 patients remained recurrence-free and 153 patients experienced a recurrence (median follow-up: 9.9 years). Median time from initial treatment to recurrence was 30.5 months (range: 2.0–238.7). Seventy-nine (69.9%) patients with recurrences and 826 (37.9%) patients in the recurrence-free group died of metastatic uveal melanoma (p<0.001). Median time from initial treatment to melanoma-related death was 4.9 years (1.0–31.8) for patients who developed recurrences and 4.3 years (0.59–33.8) for patients who did not (p=0.17). Five-year and 10-year probabilities of melanoma-related mortality were 9.5% and 15.0%, respectively, in patients without local recurrences compared with 32.0% and 46.6% in patients with recurrences (p<0.001). Conclusion These data confirm previous reports that local recurrence is associated with an increased risk of dying of melanoma and quantify the risk that can be attributed to local recurrence independent of other risk factors. This group of patients should be strongly considered for adjuvant therapies when available.

1 February 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
TSTakuto Sato
Takuto Sato
KMKamaneh Montazeri
Kamaneh Montazeri
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
ALAnne Marie Lane
Anne Marie Lane
MAMary Beth Aronow
Mary Beth Aronow
IKIvana K Kim
Ivana K Kim
PURPOSE: Somatic chromosomal alterations, particularly monosomy 3 and 8q gains, have been associated with metastatic risk in uveal melanoma (UM). Whole genome-scale evaluation of detectable alterations in cell-free DNA (cfDNA) in UM could provide valuable prognostic information. Our pilot study evaluates the correlation between genomic information using ultra-low-pass whole-genome sequencing (ULP-WGS) of cfDNA in UM and associated clinical outcomes. MATERIALS AND METHODS: ULP-WGS of cfDNA was performed on 29 plasma samples from 16 patients, 14 metastatic UM (mUM) and two non-metastatic, including pre- and post-treatment mUM samples from 10 patients treated with immunotherapy and one with liver-directed therapy. We estimated tumor fraction (TFx) and detected copy-number alterations (CNAs) using ichorCNA. Presence of 8q amplification was further analyzed using the likelihood ratio test (LRT). RESULTS: Eleven patients with mUM (17 samples) of 14 had detectable circulating tumor DNA (ctDNA). 8q gain was detected in all 17, whereas monosomy 3 was detectable in 10 of 17 samples. TFx generally correlated with disease status, showing an increase at the time of disease progression (PD). 8q gain detection sensitivity appeared greater with the LRT than with ichorCNA at lower TFxs. The only patient with mUM with partial response on treatment had a high pretreatment TFx and undetectable on-treatment ctDNA, correlating with her profound response and durable survival. CONCLUSION: ctDNA can be detected in mUM using ULP-WGS, and the TFx correlates with DS. 8q gain was consistently detectable in mUM, in line with previous studies indicating 8q gains early in primary UM and higher amplification with PD. Our work suggests that detection of CNAs by ULP-WGS, particularly focusing on 8q gain, could be a valuable blood biomarker to monitor PD in UM.